Evidence map›Paper›PMID 27667752›Full record

ArticleThe Journal of infection2017

Respiratory viruses and influenza-like illness: Epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample.

Sylvia Taylor, Pio Lopez, Lily Weckx, Charissa Borja-Tabora, Rolando Ulloa-Gutierrez, Eduardo Lazcano-Ponce, Angkool Kerdpanich, Miguel Angel Rodriguez Weber, Abiel Mascareñas de Los Santos, Juan-Carlos Tinoco and 12 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of infection, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01051661 (A Study to Evaluate the Safety and Efficacy of A/California/7/2009), which is not on this map. Cited by 77 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 3 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01051661 phase3completednot on this map

A Study to Evaluate the Safety and Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Children Aged 6 Months to Less Than 10 Years of Age

TypeinterventionalSponsorGlaxoSmithKlineRan2010 to 2011Enrolled6,154ConditionsInfluenzaArmsGSK Biologicals' investigational vaccine GSK2340274A (alternative formulations), GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations), Placebo
3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 3 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Prevalence of respiratory viruses in stable and acute asthma: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026
    Pooled it
  2. Pervasive refusal syndrome: systematic review of case reports.European child & adolescent psychiatry · 2021
    Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 12 institutions in 9 countries.

Sylvia TaylorGSK Vaccines, Wavre, Belgium. Electronic address: sylvia.m.taylor@GSK.com.
Pio LopezCentro de Estudios en Infectologia Pediatrica, Cali, Colombia.
Lily WeckxPediatric Infectious Diseases, Department of Pediatrics, Universidade Federal de São Paulo, São Paulo, Brazil.
Charissa Borja-TaboraResearch Institute for Tropical Medicine, Department of Health, Alabang, Muntinlupa City, Philippines.
Rolando Ulloa-GutierrezInstituto Costarricense de Investigaciones Clínicas, San José, Costa Rica.
Eduardo Lazcano-PonceNational Institute of Public Health of Mexico, Cuernavaca Morelos, Mexico.
Angkool KerdpanichInfectious Diseases Unit, Department of Pediatrics, Phramongkutklao Hospital, Thailand.
Miguel Angel Rodriguez WeberInstituto Nacional de Pediatría de Mexico, Mexico.
Abiel Mascareñas de Los SantosServicios Medicos Universidad Autonoma de Nuevo Leon, Monterrey, Mexico.
Juan-Carlos TinocoHospital General de Durango, Durango, Mexico.
Marco Aurelio P SafadiFaculdade de Ciências Médicas da Santa Casa de São Paulo and Associação Fundo de Incentivo à Pesquisa, Department of Pediatrics, São Paulo, Brazil.
Fong Seng LimNational Healthcare Group Polyclinics, National University of Singapore, Singapore.
Marcela Hernandez-de MezervilleInstituto Costarricense de Investigaciones Clínicas, San José, Costa Rica.
Idis FaingezichtInstituto Costarricense de Investigaciones Clínicas, San José, Costa Rica.
Aurelio Cruz-ValdezNational Institute of Public Health of Mexico, Cuernavaca Morelos, Mexico.
Yang FengGSK Vaccines, Wavre, Belgium.
Ping LiGSK Vaccines, King of Prussia, PA, USA.
Serge DurviauxGSK Vaccines, Wavre, Belgium.
Gerco HaarsGSK Vaccines, Wavre, Belgium.
Sumita Roy-GhantaGSK Vaccines, King of Prussia, PA, USA.
David W VaughnGSK Vaccines, King of Prussia, PA, USA.
Terry NolanMurdoch Children's Research Institute and Melbourne School of Population and Global Health, University of Melbourne, Carlton, Victoria, Australia.
GlaxoSmithKline (Belgium) · BEInstituto Costarricense de Investigación y Enseñanza en Nutrición y Salud · CRInstituto Nacional de Salud Pública · MXAsociación Colombiana de Infectología · COAssociação Fundo de Incentivo à Pesquisa · BRInstituto Nacional de Pediatria · MXNational University of Singapore · SGPhramongkutklao Hospital · THResearch Institute for Tropical Medicine · PHUniversidad Autónoma de Nuevo León · MXUniversidade Federal de São Paulo · BRUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBetter population data on respiratory viruses in children in tropical and southern hemisphere countries is needed.

methodsThe epidemiology of respiratory viruses among healthy children (6 months to <10 years) with influenza-like illness (ILI) was determined in a population sample derived from an influenza vaccine trial (NCT01051661) in 17 centers in eight countries (Australia, South East Asia and Latin America). Active surveillance for ILI was conducted for approximately 1 year (between February 2010 and August 2011), with PCR analysis of nasal and throat swabs.

results6266 children were included, of whom 2421 experienced 3717 ILI episodes. Rhinovirus/enterovirus had the highest prevalence (41.5%), followed by influenza (15.8%), adenovirus (9.8%), parainfluenza and respiratory syncytial virus (RSV) (both 9.7%), coronavirus (5.6%), human metapneumovirus (5.5%) and human bocavirus (HBov) (2.0%). Corresponding incidence per 100 person-years was 29.78, 11.34, 7.03, 6.96, 6.94, 4.00, 3.98 and 1.41. Except for influenza, respiratory virus prevalence declined with age. The incidence of medically-attended ILI associated with viral infection ranged from 1.03 (HBov) to 23.69 (rhinovirus/enterovirus). The percentage of children missing school or daycare ranged from 21.4% (HBov) to 52.1% (influenza).

conclusionsActive surveillance of healthy children provided evidence of respiratory illness burden associated with several viruses, with a substantial burden in older children.

Indexed as

AustraliaChildChild, PreschoolCoronavirusCoronavirus InfectionsFemaleHealthy VolunteersHumansIncidenceInfantInfluenza, HumanInternationalityMaleMetapneumovirusParamyxoviridae InfectionsPicornaviridae InfectionsActive surveillanceHealthy childrenIncidenceInfluenza-like illnessPrevalenceRespiratory viruses

Identifiers

PMID27667752
PMCPMC7112512
OpenAlexW2523381283

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.